Xiao Dong Wang
Gründer bei BEIGENE, LTD.
Vermögen: 128 Mio $ am 30.04.2024
Aktive Positionen von Xiao Dong Wang
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BEIGENE, LTD. | Direktor/Vorstandsmitglied | 01.02.2016 | - |
Gründer | 28.10.2010 | - | |
Vorsitzender | 28.10.2010 | 27.01.2016 | |
CLOVER BIOPHARMACEUTICALS, LTD. | Direktor/Vorstandsmitglied | 16.03.2021 | - |
National Academy of Sciences
National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC. | Corporate Officer/Principal | 01.01.2004 | - |
National Institute of Biological Sciences | Direktor/Vorstandsmitglied | 01.01.2003 | - |
Gründer | 01.01.2003 | - | |
Chinese Academy of Sciences | Corporate Officer/Principal | 01.01.2013 | - |
Sironax Ltd.
Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Vorsitzender | 01.09.2017 | - |
Gründer | 01.09.2017 | - | |
Tsinghua University | Corporate Officer/Principal | 01.01.2020 | - |
Karriereverlauf von Xiao Dong Wang
Ehemalige bekannte Positionen von Xiao Dong Wang
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
The University of Texas Southwestern Medical Center | Corporate Officer/Principal | 01.01.2001 | 01.01.2010 |
Howard Hughes Medical Institute, Inc.
Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Howard Hughes Medical Institute, Inc. engages in the provision of biomedical research services and science education programs. It funds grants to both institutions and individuals in support of a wide range of science and research-related initiatives, including precollege and undergraduate science education, pre- and post-doctoral research fellowships, and international research activities. The company was founded by Howard R. Hughes in 1953 and is headquartered in Chevy Chase, MD. | Corporate Officer/Principal | - | - |
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Xiao Dong Wang
Beijing Normal University | Undergraduate Degree |
The University of Texas Southwestern Medical Center | Doctorate Degree |
Statistik
International
China | 7 |
Vereinigte Staaten | 5 |
Cayman Islands | 2 |
Operativ
Corporate Officer/Principal | 6 |
Founder | 4 |
Director/Board Member | 3 |
Sektoral
Health Technology | 5 |
Consumer Services | 5 |
Miscellaneous | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
BEIGENE, LTD. | Health Technology |
CLOVER BIOPHARMACEUTICALS, LTD. | Health Technology |
Private Unternehmen | 5 |
---|---|
Joyant Pharmaceuticals, Inc.
Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Health Technology |
Howard Hughes Medical Institute, Inc.
Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Howard Hughes Medical Institute, Inc. engages in the provision of biomedical research services and science education programs. It funds grants to both institutions and individuals in support of a wide range of science and research-related initiatives, including precollege and undergraduate science education, pre- and post-doctoral research fellowships, and international research activities. The company was founded by Howard R. Hughes in 1953 and is headquartered in Chevy Chase, MD. | Miscellaneous |
National Academy of Sciences
National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC. | Commercial Services |
National Institute of Biological Sciences | |
Sironax Ltd.
Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Health Technology |
- Börse
- Insiders
- Xiao Dong Wang
- Erfahrung